Sage Journals: Discover world-class research

Abstract

Purpose:

Catecholamines are first-line vasopressors for hemodynamic support in distributive shock but are associated with adverse effects, which may be mitigated with noncatecholamine vasopressors. Angiotensin II (ATII) is a noncatecholamine vasopressor recently approved for the management of distributive shock, but limited data support its clinical utility. The purpose of this study was to describe our institution’s usage of ATII including patient outcomes (eg, response to therapy, safety profile).

Materials and Methods:

Patients who received ATII at our institution were included. Patient demographics, degree of concordance with institutional ATII use guidelines, safety profile of ATII, and response to therapy (1 and 3 hours after ATII initiation) were collected.

Results:

A total of 16 patients received ATII for distributive shock. The median Sequential Organ Failure Assessment score at the time of ATII initiation was 16.5 (interquartile range: 15.8-20.0). Fourteen (87.5%) patients met institutional guidelines for ATII use; 10 (62.5%) and 8 (50.0%) patients met our definition for response at 1 and 3 hours, respectively. No patients developed thrombotic or infectious complications after receiving ATII.

Conclusions:

In this cohort, ATII appears to be well tolerated in patients with a high predicted mortality. Future studies evaluating the clinical efficacy of ATII are needed to determine its role in the management of distributive shock.

Keywords

angiotensin II critical care distributive shock septic shock

Get full access to this article

View all access options for this article.

References

Brown

Lanspa

Jones

, et al. Survival after shock requiring high-dose vasopressor therapy. Chest. 2013;143(3):664–671.

Mayr

Yende

Angus

. Epidemiology of severe sepsis. Virulence. 2014;5(1):4–11.

Rhodes

Evans

Alhazzani

, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;43(3):304–377.

De Backer

Biston

Devriendt

, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789.

Zhang

Chen

Huang

, et al. Severe sepsis; low expression of the renin-angiotensin system is associated with poor prognosis. Exp Ther Med. 2014;7(5):1342–1346.

Mehta

Griendling

. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292(1):C82–C97.

Khanna

English

Wang

, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419–430.

Active Ingredient: Angiotensin II . RED BOOK Online. Micromedex Healthcare Series [Database Online]. Greenwood Village, CO: Truven Health Analytics; 2019. Accessed April 2, 2019.

Charlson

Szatrowski

Peterson

Gold

. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251.

10.

Vincent

Moreno

Takala

, et al. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22(7):707–710.

11.

Knaus

Draper

Wagner

Zimmerman

. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829.

12.

Moskowitz

Omar

Chase

, et al. Reasons for death in patients with sepsis and septic shock. J Crit Care. 2017;38:284–288.

13.

Bassi

Park

Azevedo

. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract. 2013;2013:654708.

14.

Omar

Zedan

Nugent

. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci. 2015;349(1):80–88.

15.

Tumlin

Murugan

Deane

, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46(6):949–957.

16.

Ham

Boldt

McCrudy

, et al. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. Ann Intensive Care. 2019;9(1):63.

17.

Rose

Center for Drug Evaluation and Research. Application number: 209360Orig1s000: Summary review. Food and Drug Administration website. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209360Orig1s000SumR.pdf. Updated December 21, 2017. Accessed July 14, 2019.

18.

Chawla

Chen

Bellomo

Tidmarsh

. Angiotensin converting enzyme defects in shock: implications for future therapy. Critical Care. 2018;22(1):274.

19.

Russell

Walley

Singer

, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–887.

20.

Busse

Wang

Chalikonda

, et al. Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med. 2017;45(8):1285–1294.

21.

Millar

Nally

Thomson

. Angiotensin II potentiates methacholine-induced bronchoconstriction in human airway both in vitro and in vivo. Eur Respir J. 1995;8(11):1838–1841.

22.

Abril

Khanna

Kroll

McNamara

Handisides

Busse

. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data. J Crit Care. 2019;50:188–194.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB

0.11 MB

0.10 MB

0.03 MB

A Retrospective Review of Angiotensin II Use in Adult Patients With Refractory Distributive Shock